Sarepta's SRP-1003 Shows Nuclear Knockdown of Toxic RNA in DM1 Preclinical Data
Event summary
- Sarepta presented preclinical data at the 2026 Oligonucleotide Therapeutics Society Annual Meeting showing SRP-1003 achieved up to 80% knockdown of pathogenic DMPK RNA in both nuclear and cytoplasmic compartments.
- SRP-1003 demonstrated dose-dependent reductions in toxic nuclear RNA foci across multiple DM1 models and methods.
- The therapy corrected MBNL-dependent mis-splicing, providing functional evidence of nuclear activity.
- Sarepta expects to share Phase 1/2 clinical trial results for SRP-1003 later this year.
The big picture
Sarepta's preclinical data for SRP-1003 represents a significant step in addressing the underlying biology of myotonic dystrophy type 1 (DM1), a progressive multisystem disorder with no current cure. The ability to target and degrade toxic nuclear RNA in DM1 could set a new standard for siRNA therapies in genetic diseases. The upcoming Phase 1/2 trial results will be critical in determining the therapeutic potential of SRP-1003 and its commercial viability in a competitive rare disease market.
What we're watching
- Clinical Validation
- Whether the Phase 1/2 trial results will confirm the preclinical efficacy of SRP-1003 in human patients.
- Regulatory Pathway
- The pace at which Sarepta can advance SRP-1003 through regulatory approvals given the novel mechanism of action.
- Competitive Positioning
- How Sarepta's progress with SRP-1003 will impact its leadership position in precision genetic medicine for rare diseases.
Related topics
